ID   HSC-3
AC   CVCL_1288
SY   HSC 3; HSC3
DR   BTO; BTO:0002025
DR   CLO; CLO_0051569
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   BioGRID_ORCS_Cell_line; 647
DR   BioSample; SAMN01821684
DR   BioSample; SAMN03471639
DR   BioSample; SAMN10987855
DR   cancercelllines; CVCL_1288
DR   Cell_Model_Passport; SIDM00589
DR   CGH-DB; 364-2
DR   ChEMBL-Cells; CHEMBL3307947
DR   ChEMBL-Targets; CHEMBL612279
DR   Cosmic; 907061
DR   Cosmic; 930331
DR   Cosmic; 932148
DR   Cosmic; 1042299
DR   Cosmic; 1046028
DR   Cosmic; 1118789
DR   Cosmic; 1120698
DR   Cosmic; 1123039
DR   Cosmic; 1140781
DR   Cosmic; 1219865
DR   Cosmic; 1530744
DR   Cosmic; 1571802
DR   Cosmic; 2266784
DR   Cosmic; 2546836
DR   Cosmic-CLP; 907061
DR   DepMap; ACH-000778
DR   EGA; EGAS00001000978
DR   GDSC; 907061
DR   GEO; GSM243522
DR   GEO; GSM301579
DR   GEO; GSM827234
DR   GEO; GSM850383
DR   GEO; GSM887134
DR   GEO; GSM888205
DR   GEO; GSM950317
DR   GEO; GSM950318
DR   GEO; GSM950319
DR   GEO; GSM950320
DR   GEO; GSM1669904
DR   IARC_TP53; 1100
DR   JCRB; JCRB0623
DR   LiGeA; CCLE_819
DR   LINCS_LDP; LCL-1217
DR   Millipore; SCC193
DR   PharmacoDB; HSC3_620_2019
DR   PRIDE; PXD029420
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1288
DR   PubChem_Cell_line; CVCL_1288
DR   RCB; RCB1975
DR   TKG; TKG 0484
DR   Ubigene; YC-C063
DR   Wikidata; Q54896384
RX   PubMed=1570156;
RX   PubMed=2228902;
RX   PubMed=2585303;
RX   PubMed=7591301;
RX   PubMed=9023415;
RX   PubMed=9290701;
RX   PubMed=9813718;
RX   PubMed=10069537;
RX   PubMed=10741724;
RX   PubMed=11416159;
RX   PubMed=11755821;
RX   PubMed=12738951;
RX   PubMed=16127291;
RX   PubMed=17052259;
RX   PubMed=17325662;
RX   PubMed=17599052;
RX   PubMed=17719389;
RX   PubMed=18097548;
RX   PubMed=18423281;
RX   PubMed=18973137;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=21362583;
RX   PubMed=22460905;
RX   PubMed=24627082;
RX   PubMed=26754630;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=31068700;
RX   PubMed=31978347;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Japanese.
CC   Doubling time: 20.28 hours (PubMed=21362583); 20 hours (PubMed=24627082); ~60 hours (Note=Lot 121498), ~44 hours (Note=Lot 07242009), ~52 hours (Note=Lot 02022015), 42-65 hours (Note=Lot 07112016), ~37 hours (Note=Lot 06112018) (JCRB=JCRB0623).
CC   HLA typing: A*02:01,24:02; B*48:01,52:01; C*08:03,12:02 (PubMed=9023415).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu120Ter (c.358G>T); Zygosity=Homozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Gly (c.1634A>G); ClinVar=VCV000013656; Zygosity=Unspecified (PubMed=18097548).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys305fs (c.912_913insTAAG); Zygosity=Unspecified (PubMed=1570156; PubMed=10741724; DepMap).
CC   Omics: Array-based CGH.
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0.32%; Native American=0%; East Asian, North=85.88%; East Asian, South=12.09%; South Asian=0%; European, North=0%; European, South=1.7% (PubMed=30894373).
CC   Miscellaneous: STR profile from personal communication of Sano D.
CC   Derived from site: Metastatic; Cervical lymph node; UBERON=UBERON_0002429.
ST   Source(s): Cosmic-CLP; Direct_author_submission; JCRB; Millipore; PubMed=11416159; RCB; TKG
ST   Amelogenin: X,Y
ST   CSF1PO: 11
ST   D13S317: 12
ST   D16S539: 9
ST   D18S51: 15
ST   D21S11: 30,31.2
ST   D3S1358: 17
ST   D5S818: 11,13
ST   D7S820: 13
ST   D8S1179: 12
ST   FGA: 22,26
ST   Penta D: 10
ST   Penta E: 11,15
ST   TH01: 6,9.3
ST   TPOX: 8
ST   vWA: 14,17
DI   NCIt; C4648; Tongue squamous cell carcinoma
DI   ORDO; Orphanet_457252; Squamous cell carcinoma of the oral tongue
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   64Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 42
//
RX   PubMed=1570156;
RA   Sakai E., Tsuchida N.;
RT   "Most human squamous cell carcinomas in the oral cavity contain
RT   mutated p53 tumor-suppressor genes.";
RL   Oncogene 7:927-933(1992).
//
RX   PubMed=2228902; DOI=10.1007/BF02624609;
RA   Rikimaru K., Toda H., Tachikawa N., Kamata N., Enomoto S.;
RT   "Growth of the malignant and nonmalignant human squamous cells in a
RT   protein-free defined medium.";
RL   In Vitro Cell. Dev. Biol. 26:849-856(1990).
//
RX   PubMed=2585303; DOI=10.1111/j.1600-0714.1989.tb01570.x;
RA   Momose F., Araida T., Negishi A., Ichijo H., Shioda S., Sasaki S.;
RT   "Variant sublines with different metastatic potentials selected in
RT   nude mice from human oral squamous cell carcinomas.";
RL   J. Oral Pathol. Med. 18:391-395(1989).
//
RX   PubMed=7591301; DOI=10.1002/ijc.2910640504;
RA   Eura M., Ogi K., Chikamatsu K., Lee K.D., Nakano K., Masuyama K.,
RA   Itoh K., Ishikawa T.;
RT   "Expression of the MAGE gene family in human head-and-neck squamous-cell
RT   carcinomas.";
RL   Int. J. Cancer 64:304-308(1995).
//
RX   PubMed=9023415; DOI=10.1006/cimm.1996.1062;
RA   Seki N., Hoshino T., Kikuchi M., Hayashi A., Itoh K.;
RT   "HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating
RT   lymphocytes of patients with non-small cell lung cancer.";
RL   Cell. Immunol. 175:101-110(1997).
//
RX   PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D;
RA   Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T.,
RA   Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M.,
RA   Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.;
RT   "Screening the p53 status of human cell lines using a yeast functional
RT   assay.";
RL   Mol. Carcinog. 19:243-253(1997).
//
RX   PubMed=9813718; DOI=10.1016/S1368-8375(98)80003-1;
RA   Matsui T., Ota T., Ueda Y., Tanino M., Odashima S.;
RT   "Isolation of a highly metastatic cell line to lymph node in human
RT   oral squamous cell carcinoma by orthotopic implantation in nude
RT   mice.";
RL   Oral Oncol. 34:253-256(1998).
//
RX   PubMed=10069537; DOI=10.1111/j.1600-0714.1999.tb02006.x;
RA   Hoteiya T., Hayashi E., Satomura K., Kamata N., Nagayama M.;
RT   "Expression of E-cadherin in oral cancer cell lines and its
RT   relationship to invasiveness in SCID mice in vivo.";
RL   J. Oral Pathol. Med. 28:107-111(1999).
//
RX   PubMed=10741724;
RA   Eura M., Chikamatsu K., Katsura F., Obata A., Sobao Y., Takiguchi M.,
RA   Song Y.-S., Appella E., Whiteside T.L., DeLeo A.B.;
RT   "A wild-type sequence p53 peptide presented by HLA-A24 induces
RT   cytotoxic T lymphocytes that recognize squamous cell carcinomas of the
RT   head and neck.";
RL   Clin. Cancer Res. 6:979-986(2000).
//
RX   PubMed=11416159; DOI=10.1073/pnas.121616198;
RA   Masters J.R.W., Thomson J.A., Daly-Burns B., Reid Y.A., Dirks W.G.,
RA   Packer P., Toji L.H., Ohno T., Tanabe H., Arlett C.F., Kelland L.R.,
RA   Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.;
RT   "Short tandem repeat profiling provides an international reference
RT   standard for human cell lines.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001).
//
RX   PubMed=11755821; DOI=10.1016/S1368-8375(01)00022-7;
RA   Niinaka Y., Haga A., Negishi A., Yoshimasu H., Raz A., Amagasa T.;
RT   "Regulation of cell motility via high and low affinity autocrine
RT   motility factor (AMF) receptor in human oral squamous carcinoma
RT   cells.";
RL   Oral Oncol. 38:49-55(2002).
//
RX   PubMed=12738951; DOI=10.1067/moe.2003.36;
RA   Sugiyama M., Bhawal U.K., Dohmen T., Ono S., Miyauchi M., Ishikawa T.;
RT   "Detection of human papillomavirus-16 and HPV-18 DNA in normal,
RT   dysplastic, and malignant oral epithelium.";
RL   Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 95:594-600(2003).
//
RX   PubMed=16127291; DOI=10.1159/000087910;
RA   Bhawal U.K., Ozaki Y., Nishimura M., Sugiyama M., Sasahira T.,
RA   Nomura Y., Sato F., Fujimoto K., Sasaki N., Ikeda M.-a., Tsuji K.,
RA   Kuniyasu H., Kato Y.;
RT   "Association of expression of receptor for advanced glycation end
RT   products and invasive activity of oral squamous cell carcinoma.";
RL   Oncology 69:246-255(2005).
//
RX   PubMed=17052259; DOI=10.1111/j.1349-7006.2006.00343.x;
RA   Kozaki K.-i., Imoto I., Pimkhaokham A., Hasegawa S., Tsuda H.,
RA   Omura K., Inazawa J.;
RT   "PIK3CA mutation is an oncogenic aberration at advanced stages of oral
RT   squamous cell carcinoma.";
RL   Cancer Sci. 97:1351-1358(2006).
//
RX   PubMed=17325662; DOI=10.1038/sj.onc.1210330;
RA   Nakaya K., Yamagata H.D., Arita N., Nakashiro K.-i., Nose M., Miki T.,
RA   Hamakawa H.;
RT   "Identification of homozygous deletions of tumor suppressor gene FAT
RT   in oral cancer using CGH-array.";
RL   Oncogene 26:5300-5308(2007).
//
RX   PubMed=17599052; DOI=10.1038/sj.onc.1210589;
RA   Suzuki E., Imoto I., Pimkhaokham A., Nakagawa T., Kamata N.,
RA   Kozaki K.-i., Amagasa T., Inazawa J.;
RT   "PRTFDC1, a possible tumor-suppressor gene, is frequently silenced in
RT   oral squamous-cell carcinomas by aberrant promoter hypermethylation.";
RL   Oncogene 26:7921-7932(2007).
//
RX   PubMed=17719389; DOI=10.1016/j.joms.2006.11.034;
RA   Erdem N.F., Carlson E.R., Gerard D.A., Ichiki A.T.;
RT   "Characterization of 3 oral squamous cell carcinoma cell lines with
RT   different invasion and/or metastatic potentials.";
RL   J. Oral Maxillofac. Surg. 65:1725-1733(2007).
//
RX   PubMed=18097548; DOI=10.3892/ijo.32.1.101;
RA   Murugan A.K., Hong N.T., Fukui Y., Munirajan A.K., Tsuchida N.;
RT   "Oncogenic mutations of the PIK3CA gene in head and neck squamous cell
RT   carcinomas.";
RL   Int. J. Oncol. 32:101-111(2008).
//
RX   PubMed=18423281; DOI=10.1016/j.joms.2007.12.036;
RA   Erdem N.F., Carlson E.R., Gerard D.A.;
RT   "Characterization of gene expression profiles of 3 different human
RT   oral squamous cell carcinoma cell lines with different invasion and
RT   metastatic capacities.";
RL   J. Oral Maxillofac. Surg. 66:918-927(2008).
//
RX   PubMed=18973137; DOI=10.1002/gcc.20626;
RA   Sugimoto T., Seki N., Shimizu S., Kikkawa N., Tsukada J., Shimada H.,
RA   Sasaki K., Hanazawa T., Okamoto Y., Hata A.;
RT   "The galanin signaling cascade is a candidate pathway regulating
RT   oncogenesis in human squamous cell carcinoma.";
RL   Genes Chromosomes Cancer 48:132-142(2009).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=21362583; DOI=10.1016/j.anl.2011.01.018;
RA   Sakakibara A., Tsukuda M., Kondo N., Ishiguro Y., Kimura M.,
RA   Fujita K., Takahashi H., Matsuda H.;
RT   "Examination of the optimal condition on the in vitro sensitivity to
RT   telomelysin in head and neck cancer cell lines.";
RL   Auris Nasus Larynx 38:589-599(2011).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=24627082; DOI=10.3892/ijo.2014.2332;
RA   Fujinaga T., Kumamaru W., Sugiura T., Kobayashi Y., Ohyama Y.,
RA   Ikari T., Onimaru M., Akimoto N., Jogo R., Mori Y.;
RT   "Biological characterization and analysis of metastasis-related genes
RT   in cell lines derived from the primary lesion and lymph node
RT   metastasis of a squamous cell carcinoma arising in the mandibular
RT   gingiva.";
RL   Int. J. Oncol. 44:1614-1624(2014).
//
RX   PubMed=26754630; DOI=10.1186/s13046-016-0284-4;
RA   Hyakusoku H., Sano D., Takahashi H., Hatano T., Isono Y., Shimada S.,
RA   Ito Y., Myers J.N., Oridate N.;
RT   "JunB promotes cell invasion, migration and distant metastasis of head
RT   and neck squamous cell carcinoma.";
RL   J. Exp. Clin. Cancer Res. 35:6.1-6.12(2016).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//